Intarcia Therapeutics

Discussion in 'Intarcia Therapeutics' started by anonymous, Mar 31, 2017 at 10:22 AM.

Tags: Add Tags
  1. Achillion Pharmaceuticals falls 25% after hepatitis C deal with J&J unit ends
    • A Johnson & Johnson pharmaceutical unit focused on the development of hepatitis C research said it will end its program amid a crowded market.
    • Janssen Sciences Ireland cited the increasing availability of a number of highly effective therapies addressing the medical need.

    Glorious Leader of Intarcia Demonstrates Expertise in Leading Strategy Committee for Achillion

    COMMITTEE COMPOSITION
    Strategy Committee
    David I. Scheer Member
    Jason S. Fisherman MD Member
    Kurt Graves Chair
     

  2. anonymous

    anonymous Guest

    Appointing marketing person as chair of strategies (WTF?) and Graves the free spending talking head who managed to con enough money from soon to be bagholder investors.

    And reason for Jansses shit canning Achillion was due to crowded market for Hep C (like they didn't know when they partnered with them which begs the question of why now) like Type II diabetes with slew of GLP-1 from big pharmas and soon in a month generic version from Teva?

    Say Graves and company - WTF is going on with approval?
     
  3. Lie about little things... Lie about big things.... Lie about everything

    Does KG have a college degree ? why does it change from "biology" to "biology and chemistry" to "chemistry" ? Have you compared the various press and public statements ? Is it charisma or lies ?

    Seems like Abbvie...

    Richard Gonzalez, who Abbott Laboratories at one time claimed obtained a master's degree from the University of Miami, attended the school for just four months, records show.

    Mr. Gonzalez, who has been tapped to head Abbott's pharmaceutical spinoff, AbbVie, attended the university from Jan. 1 to May 1, 1974, according to a school record released Monday by the National Student Clearinghouse, the organization that handles enrollment and degree verification services for many colleges.

    In filings with the U.S. Securities and Exchange Commission from 2002 to 2007, Abbott also said Mr. Gonzalez received a bachelor's degree in biochemistry from the University of Houston. Last week, the Texas school confirmed that Mr. Gonzalez was enrolled from fall 1972 to fall 1973 and did not receive a degree.
     
  4. anonymous

    anonymous Guest

    Find an MSL who works for Intarcia and thy will tell you the truth. The truth is they got bad news last month from the FDA regarding manufacturing and since they are not a public company they DO NOT have to disclose that information. Don't get your hopes up if you are considering going to work at Intarcia. IF they get approval it should be an amazing place but this is a HUGE if. Don't quit a job to come there until they get approval.
     
  5. anonymous

    anonymous Guest

    Responding to and fixing manufacturing problems cited in a CRL and underlying warning letter can take time, and FDA may spend up to six months reviewing a resubmitted application. Raffat, the stock analyst, has analyzed all warning letters in the past 20 years that specifically relate to cGMP problems on finished drug products. For this set of 31 letters, he found that it takes anywhere from four months to four years to resolve the issues. The average resolution took 17 months.
     
  6. anonymous

    anonymous Guest

    An insider in Hayward said there have been lot of hubbub in last couple of weeks with rumours of CRL and heads rolling. Pretty tense there and finger pointing. LOL Guess their feeble and quixotic attempts to fool the FDA didn't work out or something.

    BTW - anyone receive DM job offer?
     
  7. anonymous

    anonymous Guest

    CRL is often kiss of death especially for the perennial 20+ year old start-up biotech on its 1st NDA. Apparently army of new hires and consultants including McKinsey and Deloitte (ironically both were on-site at same time in Hayward) were not able to fix and undo the inherent fxck ups in Hayward. In the mean time big shots from Boston flew in to throw their weight around and bully with ZERO experience and knowledge in mfg/qa/qc/regulatory - recipe for CRL.

    $10k question is how much cash Intarcia has on hand as it will be very expensive to bring in more consultants who charges $300 to $500/hr mostly working from "home", possibility of doing another clinical study, additional equipment and associated qualification/validation, throw away the products made for launch, payroll for the bloated FTEs anticipating steep production ramp and commercial people to disrupt the Type 2 diabetes market, etc. for 18+ months.

    And as a private company Intarcia does not need to disclose something material like CRL. KG wanted it that way to run it sans scrutiny of analyst and transparency required under Sarbane Oxley. Heck in 18 months Teva generic exenatide fueled GLP-1 price wars and Novo's novel GLP-1 pill Ph 3 results may bring about demise of the "no more analog" disruptor.
     
  8. anonymous

    anonymous Guest

    A complete waste of everyone's time! Think about the people who quit good jobs to come there...BIG mistake.
     
  9. anonymous

    anonymous Guest

    They say it's not the mistake but how one handles the mistake that one can arise out of the tough situation. Many of us wondered why so many people left good local jobs from companies like Genentech to join Intarcia. Those bigshots :rolleyes: were busy building their own serfdom by hiring others to do their job. o_O It was amusing to see so many of these coveted talents get confused :confused: and stressed out :mad: in complete disbelief. :oops: More so because they were hired and paid a lot with lofty titles to clean up the the excrements. :p:D
     
  10. anonymous

    anonymous Guest

    Left to go to VERTEX ?? Why are people leaving Intarcia to join Vertex ?? Is Vertex smarter ?? Is Vertex more charming ?? Does Vertex actually sell products ?? VERTEX ???????
     
  11. said Kurt Graves, Chairman, President and CEO of Intarcia Therapeutics, Inc. "Intarcia's goal is to bring to type 2 diabetes patients, providers and payers a totally new way of delivering chronic GLP-1 therapy that is injection-free and dosed just twice per year initially, and eventually once per year.

    e·ven·tu·al·ly
    əˈven(t)SH(o͞o)əlē/
    adverb
    1. in the end, especially after a long delay, dispute, or series of problems.
      "eventually, after midnight, I arrived at the hotel"
      synonyms: in the end, in due course, by and by, in time, after some time, after a bit, finally, at last, over the long haul;
      ultimately, in the long run, at the end of the day, one day, some day, sometime, at some point, sooner or later
      "the culprit will be caught eventually"
     
  12. anonymous

    anonymous Guest

     
  13. anonymous

    anonymous Guest

    F*cking FIRED AFTER 18 MONTHS AT VERTEX. WHY ?
    WHY WOULD VERTEX FIRE THE MOST GIFTED PHARMACEUTICAL EXECUTIVE IN THE INDUSTRY ?

    WHY IS INTARCIA'S BUILDING AS CLOSE TO VERTEX AS POSSIBLE ?
    WHO AT INTARCIA HAS TO PROVE THEY ARE BETTER THAN VERTEX ?
    WHY ARE EMPLOYEES LEAVING TO COME TO VERTEX ?

    Its simple we are better than Intarcia and the people we dump work at Intarcia because they are losers.

    Vertex #1 Biotech in Boston - Way Way Better than Intarcia

    Vertex #1 Biotech CEO
     
  14. anonymous

    anonymous Guest

    Dont hold your breath
     
  15. anonymous

    anonymous Guest

    Farewell my friends, once there was a dream but now it is gone. I am too with the help of MRI best recruiter for biotech. Sometimes the grass IS greener especially if the grass under your feet have died. Please be kind and help each other.
     
  16. anonymous

    anonymous Guest

    Cut the melodrama. What gives? Whose dream? Which dream? KINDLY telling all would be helpful.
     
  17. anonymous

    anonymous Guest

    Stupid looser dont let the door hit you in the ass
     
  18. anonymous

    anonymous Guest

    Wow, looks like intarcia employs foul-mouthed big pharma losers like any other. Aparently not so special.
     
  19. anonymous

    anonymous Guest

    All the joy of big pharma remember only one person is perfect - no not Jesus
     
  20. anonymous

    anonymous Guest

    When you come to INTARCIA, your experience and contributions are valued and the spirit of innovation is very high. We are all centered on a common goal: creating therapies that can make a difference for patients. People here want to collaborate and there is an unbelievable amount of optimism. If you have unbridled talents, great ideas and a willingness to put in a very strong effort, this is your place to be. And the requirement of being a douchebag. That’s why I’m here